One-Step Catalytic Enantioselective a-Quaternary 5-Hydroxyproline Synthesis
gel chromatography (pentane/EtOAc or toluene/EtOAc
Proc. Natl. Acad. Sci. USA 1997, 94, 2805; q) M. M.
mixtures) to afford the corresponding pyrrolidine derivative
Murphy, J. R. Schullek, E. M. Gordon, M. A. Gallop, J.
4.
Am. Chem. Soc. 1995, 117, 7029.
[2] a) D. A. Cox, A. W. Johnson, A. B. Mauger, J. Chem.
Soc. 1964, 5024; b) A. B. Mauger, F. Irreverre, B.
Witkop, J. Am. Chem. Soc. 1966, 88, 2019; c) J. Y. L.
Chung, J. T. Wasicak, W. A. Arnold, C. S. May, A. M.
Nadzan, M. W. Holladay, J. Org. Chem. 1990, 55, 270;
d) M. Perez-Fernandez, A. Avenoza, J. H. Busto, J. M.
Perregrina, F. Rodriguez, ARKIVOC 2010, 191; e) R.
Sarges, J. R. Tretter, J. Org. Chem. 1974, 39, 1710; f) A.
Sacchi, P. de Caprariis, L. Mayol, G. De Marino, J. Het-
erocycl. Chem. 1995, 32, 1067; g) R. K. Olsen, K. Ram-
asamy, T. Emery, J. Org. Chem. 1984, 49, 4524; h) P. Jo-
hannesson, G. Lindberg, W. Tong, A. Gogoll, B. Syn-
nergren, F. Nyberg, A. Karln, A. Hallberg, J. Med.
Chem. 1999, 42, 4524; i) L. Manzoni, D. Aosio, L. Bel-
visi, A. Bracci, M. Colombo, D. Invernizzi, C. Scolasti-
co, J. Org. Chem. 2005, 70, 4124, and references cited
therein.
[3] For the use of polysubstituted a-quaternary proline de-
rivatives as hepatitis C virus RNA-dependent poly-
merase inhibitors and potential effective antiviral
agents see: a) M. J. Slatter, E. M. Amphlett, D. M. An-
drews, G. Bravi, G. Burton, A. G. Cheasty, J. A. Cor-
field, M. R. Ellis, R. H. Fenwick, S. Fernandes, R.
Guidetti, D. Haigh, C. D. Hartley, P. D. Howes, D. L.
Jackson, R. L. Jarvest, V. L. H. Lovegrove, K. J. Med-
hurst, N. R. Parry, H. Price, P. Shah, O. M. P. Singh, R.
Stocker, P. Thommes, C. Wilkinson, A. Sonacott, J.
Med. Chem. 2007, 50, 897; b) G. Burton, T. W. Ku, T. J.
Carr, T. Kiesow, T. R. Sarisky, J. Lin-Goerke, A. Baker,
D. L. Earnshaw, G. A. Hofmann, R. M. Keenan, D.
Dhanak, Bioorg. Med. Chem. Lett. 2005, 15, 1553. Sali-
nosporamide natural products 1a and 1b are proteo-
some inhibitors with promising cancer chemotherapeu-
tic activities, see: c) T. A. M. Gulder, B. S. Moore,
Angew. Chem. 2010, 122, 9534; Angew. Chem. Int. Ed.
2010, 49, 9346. A 5-oxoproline derivative containing
the structural motif 1c is present in bioactive N-acylat-
ed lipooligosaccharides of mycobacteria see: d) Y.
Rombouts, E. Elass, C. Biot, E. Maes, B. Coddeville, A.
Burguire, C. Tokarski, E. Buisine, X. Trivelli, L.
Kremer, Y. Guerardel, J. Am. Chem. Soc. 2010, 132,
16073.
[4] a) D. Rane, M. P. Sibi, Chim. Oggi 2009, 27, 14; b) M. I.
Calaza, C. Cativiela, Eur. J. Org. Chem. 2008, 3427. For
selected reviews on quaternary stereocenters see: c) J.
Christoffers, A. Mann, Angew. Chem. Int. Ed. 2001, 40
4591; d) B. M. Trost, C. Jiang, Synthesis 2006, 369; e) J.
Christoffers, A. Baro, Quaternary Stereocenters: Chal-
lenges and Solutions for Organic Synthesis, Wiley-VCH,
Weinheim, 2006; f) P. G. Cozzi, R. Hilgraf, N. Zimmer-
mann, Eur. J. Org. Chem. 2007, 5969.
[5] For reviews see: a) C. Nꢃjera, J. M. Sansano, Angew.
Chem. 2005, 117, 6428; Angew. Chem. Int. Ed. 2005, 44,
6272; b) S. Karlsson, H.-E. Hçgberg, Org. Prep.
Proced. Int. 2001, 33, 103; c) K. V. Gothlef, K. A. Jør-
gensen, Chem. Soc. Rev. 1998, 27, 863; d) K. V. Gothelf,
Synthesis 2002, 211; e) L. M. Stanley, M. P. Sibi, Chem.
Rev. 2008, 108, 2887; f) H. Pellieser, Tetrahedron 2007,
63, 3235.
Typical Experimental Procedure for the Synthesis of
a-Quaternary Proline Derivatives 7 from 4
BF3·Et2O (78.1 mg, 67 mL, 0.55 mmol) was added to a stirred
solution of the pyrrolidine
4 (0.50 mmol) and Et3SiH
(58.1 mg, 80 mL, 0.50 mmol) in CH2Cl2 (15 mL) at ꢀ788C
under an N2 atmosphere. After 30 min BF3·Et2O (78.1 mg,
67 mL, 0.55 mmol) and Et3SiH (58.1 mg, 80 mL, 0.50 mmol)
were added once again, and the reaction mixture was left at
room temperature over night. The reaction mixture was di-
luted with pentane/EtOAc and then directly loaded and pu-
rified by silica gel chromatography (3:1 pentane/EtOAc!
100% EtOAc) to afford 7 as a colourless oil.
Supporting Information
Experimental procedures, full spectroscopic data for all new
described compounds, NMR spectra, HPLC traces and HR
mass spectra are available in the Supporting Information.
Acknowledgements
We thank European Union and Carl Trygger foundation for
financial support. The Berzelii Center EXSELENT is finan-
cially supported by Swedish National Research Council (VR)
and the Swedish Governmental Agency for Innovations Sys-
tems (VINNOVA).
References
[1] For reviews see: a) S. Hanessian, ChemMedChem.
2006, 1, 1300; b) G. Pandey, P. Banerjee, S. R. Gadre,
Chem. Rev. 2006, 106, 4484; c) Y. Cheng, Z.-T Huang,
M. X. Wang, Curr. Org. Chem. 2004, 8, 325; d) P.
Garner, H. U. Kaniskan, Curr. Org. Synth. 2010, 7, 348;
e) I. J. Enedy, W. A. Zaman, S. Sakamuri, A. P. Kozi-
kowzki, K. M. Johnson, S. Wang, Bioorg. Med. Chem.
Lett. 2001, 11, 1113; f) R. Grigg, Chem. Soc. Rev. 1987,
16, 89; g) E. De Clerq, Nature Drug Disc. 2006, 5,
1015; h) S. Hanessian, M. Bayrakdarian, X. Luo, J. Am.
Chem. Soc. 2002, 124, 4716. For selected reviews on the
application of chiral pyrrolidine derivatives as catalysts
see: i) P. I. Dalko, L. Moisan, Angew. Chem. Int. Ed.
2004, 116, 5248; Angew. Chem. Int. Ed. 2004, 43, 5138;
j) S. Mukherjee, J. W. Yang, S. Hoffmann, B. List,
Chem. Rev. 2007, 107, 5471; k) A. Erkkilꢂ, I. Majander,
P. M. Pihko, Chem. Rev. 2007, 107, 5416; l) A. Berkes-
sel, H. Grçger Asymmetric Organocatalysis, Wiley-
VCH, Weinheim, 2005. For selected examples in diver-
sity-oriented synthesis see: m) M. M.-C. Lo, C. S.
Neiman, S. Nagayama, E. O. Perlstein, S. L. Schreiber,
J. Am. Chem. Soc. 2004, 126, 16077; n) S. Hanessian,
M. Bayrakdarian, Tetrahedron Lett. 2002, 43, 9441;
o) S. Hanessian, M. Bayrakdarian, Bioorg. Med. Chem.
Lett. 2000, 10, 427; p) D. MacClean, J. R. Schullek,
M. M. Murphy, Z.-J. Ni, E. M. Gordon, M. A. Gallop,
Adv. Synth. Catal. 2012, 354, 1156 – 1162
ꢀ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
1161